Log in or register to see all Alerts
New HTA Decisions in Scotland
December 2019
Drug name
CUPRIOR® (trientine tetrachlorhydrate)
Company
GMP-Orphan United Kingdom Ltd
Decision date
11/11/2019
Therapeutic area
Genetic conditions
Therapeutic sub area
Genetic conditions: general and other
Decision
Recommended
Indication
The treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy.
Decision Detail
Following an abbreviated submission, trientine tetrahydrochloride (Cuprior®) is accepted for use within NHS Scotland.
Summary
Trientine tetrahydrochloride is an alternative to another formulation of trientine with a lower budget impact.